This episode is the second part of a presentation on metastatic colorectal cancer care. Oncology experts review cases of patients with metastatic colorectal cancer to discuss testing for mutations and biomarkers, appropriate selection of treatment regimens, and management.
To access episode 1, click here.
After completing this activity, participants should be better able to:
- Implement recommended testing for mutations and biomarkers that impact metastatic colorectal cancer (mCRC)
- Plan strategies for incorporating novel agents into the treatment of patients with mCRC
- Apply recommended strategies to identify and manage toxicities of novel agents for mCRC
Oncology NPs, PAs, and RNs
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 0.50, which includes 0.50 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until March 20, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Susan Moench, PhD, PA-C, Edison, New Jersey
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credits for learning and change.
This program is cosupported by educational grants from Bristol-Myers Squibb; Eisai; and Merck Sharp & Dohme Corp.
This activity is supported by an educational grant from Merck Sharp & Dohme Corp.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Andrews: fees for non-CME/CE services: Genentech.
Dr Eng: consulting fees: Amgen, GlaxoSmithKline, Hoopika, Natera; contracted research (paid to institution): Merck, Pfizer.
Dr Hubbard: advisor: BeiGene; advisor/researcher: Bayer, Boston Biomedical, G1 Therapeutics, Hutchison MediPharma, Incyte, Merck, Pionyr Immunotherapeutics, Seagen, Senhwa Pharmaceuticals, Roche, Treos Bio, TriOncology, Trovogene.
Dr Moench: independent contractor: Merck.
None of the members of the PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Listen to the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 100%.
The estimated time to complete this activity is 0.50 hours.
Release date: March 21, 2022
Expiration date: March 20, 2023
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 103421-POD3B